Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn

Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, intervent...

Full description

Saved in:
Bibliographic Details
Main Authors: Molly R. Sherwood, Bethany M. Weathersby, Marion E. Granger Howard, Kara B. Markham
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Children
Subjects:
Online Access:https://www.mdpi.com/2227-9067/12/7/822
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850077636975394816
author Molly R. Sherwood
Bethany M. Weathersby
Marion E. Granger Howard
Kara B. Markham
author_facet Molly R. Sherwood
Bethany M. Weathersby
Marion E. Granger Howard
Kara B. Markham
author_sort Molly R. Sherwood
collection DOAJ
description Background/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history of alloimmunized pregnancy. Methods: This was a retrospective cross-sectional survey study administered online to alloimmunized patients between November 2022–February 2023. A total of 127 participants reported on 200 alloimmunized pregnancies. Distribution of pregnancy characteristics, antibodies and titers, monitoring, treatments and fetal outcomes were described and stratified where appropriate by fetal antigen status and disease severity. Outcomes and management practices in subsequent pregnancies following fetal loss to HDFN are reported. Results: Multiple antibodies were present in 42% of pregnancies with known antibody type (80/192). Titers reached critical levels (any titer for Anti-K; ≥16 for all other antibodies) in 71% (125/176) of pregnancies where titer was reported. Among fetal antigen positive pregnancies with critical titers, intrauterine transfusions were conducted in 40% (42/106), intravenous immunoglobulin was administered in 14% (15/106), plasmapheresis in 7% (7/106), and phenobarbital in 9% (9/106). Complications from transfusion were reported in 38% of pregnancies receiving intrauterine transfusion (17/45). Fetal death due to HDFN or complications from intrauterine transfusion was reported in 9% of antigen positive pregnancies with critical titers (10/106) and 16% of pregnancies receiving intrauterine transfusion (7/45). Conclusions: Disease presentation and severity complements previous research in this disease population, however, monitoring practices were diverse. Fetal death and intrauterine complication rates were higher than those previously reported in large international referral centers. Development of best practices and centralized referral centers may improve disease outcomes.
format Article
id doaj-art-c96b4e72a130499186b678c9b02f8cc1
institution DOAJ
issn 2227-9067
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Children
spelling doaj-art-c96b4e72a130499186b678c9b02f8cc12025-08-20T02:45:45ZengMDPI AGChildren2227-90672025-06-0112782210.3390/children12070822Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and NewbornMolly R. Sherwood0Bethany M. Weathersby1Marion E. Granger Howard2Kara B. Markham3Allo Hope Foundation, 1655 N McFarland Blvd, Suite 256, Tuscaloosa, AL 35406, USAAllo Hope Foundation, 1655 N McFarland Blvd, Suite 256, Tuscaloosa, AL 35406, USADepartment of Epidemiology, University of South Carolina, Columbia, SC 29208, USADepartment of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, OH 45267-0526, USABackground/Objectives: Pregnancies complicated by red cell alloimmunization can progress to hemolytic disease of the fetus and newborn (HDFN), requiring close monitoring and timely intervention to prevent fetal/neonatal morbidity and mortality. This study investigated disease presentation, interventions, and outcomes in respondents with a history of alloimmunized pregnancy. Methods: This was a retrospective cross-sectional survey study administered online to alloimmunized patients between November 2022–February 2023. A total of 127 participants reported on 200 alloimmunized pregnancies. Distribution of pregnancy characteristics, antibodies and titers, monitoring, treatments and fetal outcomes were described and stratified where appropriate by fetal antigen status and disease severity. Outcomes and management practices in subsequent pregnancies following fetal loss to HDFN are reported. Results: Multiple antibodies were present in 42% of pregnancies with known antibody type (80/192). Titers reached critical levels (any titer for Anti-K; ≥16 for all other antibodies) in 71% (125/176) of pregnancies where titer was reported. Among fetal antigen positive pregnancies with critical titers, intrauterine transfusions were conducted in 40% (42/106), intravenous immunoglobulin was administered in 14% (15/106), plasmapheresis in 7% (7/106), and phenobarbital in 9% (9/106). Complications from transfusion were reported in 38% of pregnancies receiving intrauterine transfusion (17/45). Fetal death due to HDFN or complications from intrauterine transfusion was reported in 9% of antigen positive pregnancies with critical titers (10/106) and 16% of pregnancies receiving intrauterine transfusion (7/45). Conclusions: Disease presentation and severity complements previous research in this disease population, however, monitoring practices were diverse. Fetal death and intrauterine complication rates were higher than those previously reported in large international referral centers. Development of best practices and centralized referral centers may improve disease outcomes.https://www.mdpi.com/2227-9067/12/7/822alloimmunizationfetal hydropshemolytic anemiahemolytic diseaseintrauterine transfusionRh disease
spellingShingle Molly R. Sherwood
Bethany M. Weathersby
Marion E. Granger Howard
Kara B. Markham
Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
Children
alloimmunization
fetal hydrops
hemolytic anemia
hemolytic disease
intrauterine transfusion
Rh disease
title Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
title_full Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
title_fullStr Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
title_full_unstemmed Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
title_short Patient-Reported Disease Presentation, Interventions, and Outcomes in United States Pregnancies Affected by Alloimmunization at Risk of Hemolytic Disease of the Fetus and Newborn
title_sort patient reported disease presentation interventions and outcomes in united states pregnancies affected by alloimmunization at risk of hemolytic disease of the fetus and newborn
topic alloimmunization
fetal hydrops
hemolytic anemia
hemolytic disease
intrauterine transfusion
Rh disease
url https://www.mdpi.com/2227-9067/12/7/822
work_keys_str_mv AT mollyrsherwood patientreporteddiseasepresentationinterventionsandoutcomesinunitedstatespregnanciesaffectedbyalloimmunizationatriskofhemolyticdiseaseofthefetusandnewborn
AT bethanymweathersby patientreporteddiseasepresentationinterventionsandoutcomesinunitedstatespregnanciesaffectedbyalloimmunizationatriskofhemolyticdiseaseofthefetusandnewborn
AT marionegrangerhoward patientreporteddiseasepresentationinterventionsandoutcomesinunitedstatespregnanciesaffectedbyalloimmunizationatriskofhemolyticdiseaseofthefetusandnewborn
AT karabmarkham patientreporteddiseasepresentationinterventionsandoutcomesinunitedstatespregnanciesaffectedbyalloimmunizationatriskofhemolyticdiseaseofthefetusandnewborn